Royal jelly ( DrugBank: Royal jelly )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
49. Systemic lupus erythematosus
Clinical trials : 946 / Drugs : 722 - (DrugBank : 186) / Drug target genes : 117 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-UMIN000020859 | 2015/09/01 | 05/02/2016 | Effects of Royal Jelly Supplementation on Regulatory T Cells and Lymphocytes Apoptosis in Children with Systemic Lupus Erythematosus | Systemic Lupus Erythematosus. | two-month Royal Jelly (2 gm) treatment | Faculty of medicine, University of Assiut, Assiut 71516, Egypt. | NULL | Complete: follow-up complete | 8years-old | 17years-old | Male and Female | 30 | Not selected | Africa |